Flexion Therapeutics Inc

Flexion Therapeutics — Technical Presentation (May 2021)

10 slides from Flexion Therapeutics's technical presentation, May 11, 2021

  1. Slide 1: Interim Data from the First-in-Human Phase 1 Trial of FX201 for Osteoarthritis

    Interim Data from the First-in-Human Phase 1 Trial of FX201, An Intra-Articular, Helper-Dependent Adenoviral Gene Therapy for Osteoarthritis – Safety, Tolerability, Biodistribution, and Preliminary Evaluation of Clinical Activity in 5 Patients Scott Kelley1, Alan Kivitz2, Becca Senter1, David Golod1

  2. Slide 2: Background: Gene Therapy is Well-Suited to Treatment of OA

    Background: Gene Therapy is Well-Suited to Treatment of OA Osteoarthritis (OA) is a disabling, degenerative disease characterized by progressive pathological joint tissue changes including cartilage loss, bony outgrowths, thickening of subchondral bone, and synovial inflammation Interleukin-1 (IL-1)

  3. Slide 3: FX201: Gene therapy in Development for OA

    FX201: Gene therapy in Development for OA Helper-dependent Adenovirus (HDAd) Non-replicating, non-integrating virus based on human serotype 5 Adenovirus (Ad5) Nonclinical data show higher transduction efficiency compared to AAV IL-1Ra (Interleukin-1 Receptor antagonist) Clinically validated anti-inf

  4. Slide 4: First in Human Phase 1 Trial: Single Ascending Dose Escalation in Knee OA Patients

    FX201 First in Human Phase 1 Trial: Single Ascending Dose Escalation in Knee OA Patients NCT04119687: Patients and Methods Adult patients with moderate-to-severe knee OA (symptoms and radiographic) and prior failure of ≥2 other OA treatments were enrolled in the low-dose cohort FX201 administered to

  5. Slide 5: Safety and Biodistribution

    FX201 Safety and Biodistribution in Low-dose Cohort 5 patients dosed in low-dose cohort All patients remain in study 38-56+ weeks following treatment Safety: 4 patients experienced 15 AEs to date 2 patients experienced 5 index-knee AEs probably or possibly related to study medication Onset within th

  6. Slide 6: WOMAC-A Pain

    FX201 WOMAC-A Pain in Low-dose Cohort WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.

  7. Slide 7: KOOS Function

    FX201 KOOS Function in Low-dose Cohort *An increase in KOOS score indicates a positive/favorable response. KOOS = Knee Injury and Osteoarthritis Outcome Score. Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 52

  8. Slide 8: WOMAC-A Response

    FX201 WOMAC-A Response in Low-dose Cohort Weeks

  9. Slide 9: WOMAC-A Response Thresholds

    FX201 WOMAC-A Response Thresholds in Low-dose Cohort Number of Patients Moderate improvement (≥30%) Substantial improvement (≥50%) (n=5) (n=5) (n=5) (n=5) (n=5) (n=3) WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.

  10. Slide 10: First-in-Human Phase 1 Trial: Discussion and Future Direction

    FX201 First-in-Human Phase 1 Trial: Discussion and Future Direction Initial clinical experience with FX201 in knee OA Intra-articular treatment with FX201 in patients with knee OA generally well tolerated Substantial improvement in WOMAC-A pain intensity observed at 38-52 weeks following single admi

Flexion Therapeutics — Technical Presentation (May 2021) on 6ix